Barth H O, Berg P, Brunner G, Dammann H G, Friedl W, Franken F H, Greiner L, Groitl J, Möckel W, Müller P
Langenbecks Arch Chir. 1984;362(2):131-8. doi: 10.1007/BF01254187.
In a multicentre single-blind study, ranitidine was compared to cimetidine as prophylactic treatment against stress-induced upper gastrointestinal bleeding in seriously ill patients in the intensive care unit (ICU). 380 patients entered the study. 192 patients were treated with ranitidine 50 mg q.i.d. as i.v. bolus followed by 150 mg orally twice daily. 188 patients received cimetidine 400 mg q.i.d. intravenously and 1,000 mg daily orally in divided doses. Five patients in the ranitidine group (2.6%) and 12 in the cimetidine group (6.4%) developed gastrointestinal bleeding definitely or possibly due to stress lesions. This difference was not significant. The incidence of stress erosions or ulcerations developing during the study was 11.8% for the ranitidine group and 18.3% for the cimetidine group (non-significant difference). Adverse events in the ranitidine group were nausea, tachycardia or vomiting in 4 patients. 5 cimetidine-treated patients developed cholestasis, and 5 additional central nervous system problems. The high degree of efficacy of both drugs compared very favourably with the high incidence of stress ulceration and hemorrhage in similar untreated populations.
在一项多中心单盲研究中,将雷尼替丁与西咪替丁作为预防重症监护病房(ICU)重症患者应激性上消化道出血的治疗药物进行了比较。380名患者进入该研究。192名患者接受雷尼替丁治疗,静脉推注50mg,每日4次,随后每日口服150mg,分两次服用。188名患者接受西咪替丁治疗,静脉注射400mg,每日4次,每日口服1000mg,分剂量服用。雷尼替丁组有5名患者(2.6%)、西咪替丁组有12名患者(6.4%)出现明确或可能由应激性病变导致的胃肠道出血。这种差异不显著。研究期间,雷尼替丁组应激性糜烂或溃疡的发生率为11.8%,西咪替丁组为18.3%(差异不显著)。雷尼替丁组的不良事件为4名患者出现恶心、心动过速或呕吐。5名接受西咪替丁治疗的患者出现胆汁淤积,另有5名出现中枢神经系统问题。与未治疗的类似人群中应激性溃疡和出血的高发生率相比,这两种药物的高度疗效非常可观。